About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER

Viagra Proved Ineffective on Patients With Chronic End-stage Liver Disease

by VR Sreeraman on November 13, 2008 at 12:59 PM
Font : A-A+

 Viagra Proved Ineffective on Patients With Chronic End-stage Liver Disease

In a new study, scientists have established that sildenafil, a drug also sold as Viagra and known for treating erectile dysfunction (male impotence) and pulmonary arterial hypertension (PAH), does not influence blood flow in patients with cirrhosis.

Erectile dysfunction is a common problem affecting about half of all patients with end-stage liver disease.


The scientists found that sildenafil had no effect on the hepatic venous pressure gradient (HVPG).

In the study, the scientists aimed at finding if sildenafil increases splanchnic blood flow and changes the hepatic venous pressure gradient (HVPG) in patients with cirrhosis.

The study was conducted on ten patients with biopsy proven cirrhosis and an HVPG above 12 mmHg.

The scientists then measured the splanchnic blood flow and the HVPG during liver vein catheterization before and 80 min after oral administration of 50 mg sildenafil.

Blood flow was estimated by use of indocyanine green clearance technique and Fick's principle, with correction for non-steady state.

Though the scientists saw a decrease in arterial blood pressure80 min after administration of the phosphodiesterase type-5 inhibitor sildenafil, they were unable to demonstrate any clinical relevant influence on splanichnic blood flow, oxygen consumption or the HVPG.

It was known that selective phosphodiesterase type-5 inhibitors, such as sildenafil, represent an important advance in management of erectile dysfunction.

Scientists measured the HVPG and the estimation of splanchnic blood flow of the participants before and 80 min after oral administration of 50 mg of sildenafil.

This study reports the effects of sildenafil on the splanchnic hemodynamics in patients with biopsy proven cirrhosis and manifest portal hypertension.

Despite a small decrease in mean arterial pressure, the main finding in this study was that the splanchnic blood flow, oxygen consumption and the mean HVPG did not change 80 min after administration of sildenafil, i.e. at a time-point when a therapeutic plasma concentration of sildenafil could be documented.

The study shows that sildenafil does not induce any profound clinically relevant changes in splanchnic blood flow, oxygen consumption and HVPG.

The authors concluded that phosphodiesterase type-5 inhibition is of no use as a therapeutic agent for alleviating portal hypertension in patients with chronic end-stage liver disease.

Source: ANI
SRM

News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Top 7 Benefits of Good Oral Hygiene
Healthy and Safer Thanksgiving 2021
Long-Term Glycemic Control - A Better Measure of COVID-19 Severity
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Alcoholic Liver Disease Liver Biopsy Erectile Dysfunction Hepatitis A Liver Wilson's Disease Milk Thistle Current Treatments for Liver Cancer Fatty Liver Disease: A Growing Health Problem in India Living Donor Liver Transplant: What Are the Risks? 

Recommended Reading
Drugs In Impotence
Encyclopedia section of medindia gives information about the Impotence...
Alcoholic Liver Disease
Encyclopedia section of medindia gives general information about Alcoholic Liver Disease....
Liver Cancer - Animation
Liver is the largest organ inside the human body. It performs 500 different functions and processes ...
Liver Cancer Treatment - Animation
Liver Cancer is the uncontrolled growth of cells in the liver. The present section provides a ......
Current Treatments for Liver Cancer
Current Treatments for Liver Cancer (also known as hepatoma or hepatocellular carcinoma) can result ...
Erectile Dysfunction
Erectile dysfunction (ED) is the inability to develop or maintain an erection of the penis during se...
Fatty Liver Disease: A Growing Health Problem in India
Non alcoholic fatty liver disease (NAFLD) is the leading cause of liver dysfunction worldwide and is...
Hepatitis A
Hepatitis A is the most benign of the hepatitis viruses and usually has no long term side effects. H...
Living Donor Liver Transplant: What Are the Risks?
The risk of dying as a result of a living donor liver segment removal is between 0.2-2.0%. The risk ...
Milk Thistle
Milk Thistle is a resourceful natural plant which has many medicinal benefits. In herbal medication ...
Wilson's Disease
This is a rare inherited systemic disorder of copper metabolism, affecting the liver mainly before o...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use